BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Core Insights - BriaCell Therapeutics Corp. has published research on the mechanism of action of its next-generation personalized off-the-shelf immunotherapy, Bria-OTS+, in collaboration with the National Cancer Institute (NCI) [1][2] - The study highlights that semi-allogeneic dendritic-cell vaccines enhance anti-tumor effects by recruiting alloreactive CD4⁺ T-cells, which strengthens CD8⁺ T-cell responses against tumors [2] - The findings validate the design principle of Bria-OTS+, emphasizing the importance of partial HLA matching for effective tumor-antigen presentation and robust CD4⁺ helper responses [2] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [5] - The lead candidate, Bria-IMT, is currently being evaluated in a Phase 1/2a study for patients with metastatic recurrent breast cancer, which includes both monotherapy and combination therapy cohorts [4] Research and Development - The publication in JCI Insight provides insights into the mechanism of action of Bria-OTS+, aligning with the encouraging clinical results reported in the Phase 1/2a study for metastatic breast cancer [2][4] - Bria-OTS+ is characterized as a novel personalized, off-the-shelf, semi-allogeneic cellular immunotherapy that may address urgent unmet medical needs for cancer patients [7]